MOL THER-ONCOLYTICS 润色咨询

Molecular Therapy-Oncolytics

出版年份:暂无数据 年文章数:598 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:3.3% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2021-04-10 zhouxingzhi0329_32785698

    偏重的研究方向:医学
    经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上

    10

    展开10条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2021-07-15 malonglee

    这个杂志奔着顶刊去的,文章水平很高!

    6

    展开6条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2020-05-20 121255c0m87暂无昵称

    最近非常慢。两个月修回ahrrrrr 2020-05-10 发表::
    大家最近有投稿吗,投稿多久会分配稿号啊
    rrr136 2020-05-10 00:00:00 发表:
    大家最近有投稿吗,投稿多久会分配稿号啊

    ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-01-15 wsasdeffgcf

    偏重的研究方向:肿瘤
    经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-06-15 1881ff0ef5m

    审稿速度:12.0 | 投稿命中率:5.0
    偏重的研究方向:肿瘤
    经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。
    这是最后的拒稿信:
    Dear Dr. Fei,

    Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.

    Best regards,

    Yuman Fong, PhD
    Editor-in-Chief, Molecular Therapy - Oncolytics

    这是投稿时间线事件:
    Jun 13, 2022 Editor Decision - Reject for History of Concerns
    Jun 13, 2022 Author Submits Revision Confirmation
    Jun 13, 2022 PDF Built and Requires Approval
    Jun 09, 2022 Editor Decision - Pre-accept
    May 18, 2022 Author Submits Revision Confirmation
    May 18, 2022 PDF Built and Requires Approval
    Mar 08, 2022 Editor Decision - Minor Revision
    Oct 26, 2021 PDF Built and Requires Approval
    Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship
    Oct 25, 2021 PDF Built and Requires Approval
    Oct 25, 2021 Sent Back to Author Notice
    Oct 25, 2021 Author Notice of Manuscript Number
    Oct 25, 2021 PDF Built and Requires Approval

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2021-10-26 alks

    投稿命中率:5.0
    偏重的研究方向:肿瘤
    经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2021-05-16 PSYoung

    请问投了两周,仍然manuscript received,状态一直没变,是什么情况

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2021-10-03 Lord Megatron

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2021-01-26 leoscar

    审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0
    偏重的研究方向:肿瘤
    经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。

    Jan 25, 2021 PDF Built and Requires Approval
    Jan 11, 2021 Editor Decision - Minor Revision
    Jan 08, 2021 Author Notice of Manuscript Number
    Dec 31, 2020 Author Submits New Manuscript Confirmation
    Dec 24, 2020 PDF Built and Requires Approval
    Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向:医学<br>经验分享:投稿1个多月一直是with editor,给编辑发邮件无任何回应,查了查类似的文章,最快需要4个月,最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的,文章水平很高!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗,投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗,投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗,投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向:肿瘤<br>经验分享:with editor快半个月了,这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享一下这个杂志投稿,前后总共经历8个月,已经Pre-accept了,最后收到拒稿邮件,理由是他们审查到通讯作者之前有一篇被撤稿的文章,因此对这个文章的真实性产生了怀疑,属于株连九族的做法,撤稿的文章的作者和我这一篇的作者完全是两个团队,就因为导师是同一个所以就把我的文章给拒了,关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者,还是别投这个杂志了。<br>这是最后的拒稿信:<br>Dear Dr. Fei,<br><br>Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.<br><br>Best regards,<br><br>Yuman Fong, PhD<br>Editor-in-Chief, Molecular Therapy - Oncolytics<br><br>这是投稿时间线事件:<br>Jun 13, 2022 Editor Decision - Reject for History of Concerns <br>Jun 13, 2022 Author Submits Revision Confirmation <br>Jun 13, 2022 PDF Built and Requires Approval <br>Jun 09, 2022 Editor Decision - Pre-accept <br>May 18, 2022 Author Submits Revision Confirmation <br>May 18, 2022 PDF Built and Requires Approval <br>Mar 08, 2022 Editor Decision - Minor Revision <br>Oct 26, 2021 PDF Built and Requires Approval <br>Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship <br>Oct 25, 2021 PDF Built and Requires Approval <br>Oct 25, 2021 Sent Back to Author Notice <br>Oct 25, 2021 Author Notice of Manuscript Number <br>Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:这个期刊的编辑部里面的编辑都是尸体吗?1个多月了还是with editor,发邮件让他们撤稿,他们也不回,真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周,仍然manuscript received,状态一直没变,是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:7.21投稿 8.31第二次under review 到至今10.3,朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向:肿瘤<br>经验分享:一开始投了Molecular Therapy Nuclical acid,编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0<br>偏重的研究方向:基础<br>经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review<br>7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。<br>审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-08-06 小鬼鬼

    审稿速度:2.0 | 投稿命中率:95.0
    偏重的研究方向:基础
    经验分享:文章2022-08-02接收了,时间线如下:投稿MT被要求转投,2022.2.9同意转投 ,2.23 Under Review, 3.18 Under Review ,4.15修回,Major revision, 6.28 修回稿件,with editor;7.5:under review; 7.12 under review
    7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。
    审稿真的非常慢。是大修,但是其实改动很少,两个审稿人,1个提了一些意见,补了一点点实验;另一个直接说可以接收,修回还是非常友好的,在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑,好吧,还是慢,3周才预接收。。

    1

    展开1条回复
共85条页码: 1/9页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分